Aron Simkins, MD

GI Med Onc | @ConquerCancerFd #ASCO21 Merit Award. @GWSMHS @GWCancer @UTHimres @McgovernMed alum 🇮🇱🇻🇪

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠️ Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[Aron Simkins, MD @dr_simkins]

@TheVinodLab What was the ctDNA status post op of these patients? Was it checked before chemotherapy and cancer vaccines?

[Angela Lamarca @DrAngelaLamarca]

Waiting for two abstracts to be presented the whole @AACR #AACR26, this is one of them

Just presented, #Daraxonrasib in #mKRAS #PDAC by @EileenMOReilly

#Monotherapy in the #FirstLine
38 pts
ORR 47%
Time on tto 7.7m
PFS immature

Ongoing Phase III 303 (Dara vs GemNab+/-Dara)

[Aron Simkins, MD @dr_simkins]

@DrEricDing If you look at the data for the adjuvant vaccine and compared with SOC, and still think it's "remarkable" you truly don't understand oncology or clinical trials.

[Sofia Afonso Ferreira @sofiafonsoferre]

Good morning! ☕️

[Aron Simkins, MD @dr_simkins]

Let's take steps together at PurpleStride! https://t.co/iKDViaUl3J

[The Babylon Bee @TheBabylonBee]

Mamdani Clarifies That His Wife Only Celebrates Terrorism In Her Capacity As A Private Citizen https://t.co/ZySTxTInIO

[Bill Ackman @BillAckman]

You would think the current mayor of NYC @NYCMayor would put out a statement like this one and we wouldn’t have to rely on the previous mayor.

[Arndt Vogel @ArndtVogel]

HERIZON-GEA-01 phs-3: Zanidatamab + CTx +/- Tislelizumab in 1st line Her2+ locally advanced unresectable or mG/GEJ adenocarcinoma
#ASCOGI26
👉 ORR: 70 vs 69 vs 65%
👉 mPFS: 12.4 vs 12.4 vs 8.1 mo
👉 mOS: 26.4 vs 24.4 vs 19.2 mo
👉Clinical benefit across PD-L1 subgroups
🧐 convincing data, new SOC?!
@myesmo @ASCO

[Aron Simkins, MD @dr_simkins]

@GIMedOnc @JazzPharma How can this be the new SOC if it wasn't compared to a proper IO/Transtuzumab combination?

[Aron Simkins, MD @dr_simkins]

@DrRishabhOnco No neoadjuvant chemoIO, Arm1 is not the SOC anymore

[Mike Lee @SenMikeLee]

USA: not recognizing Spain in the Americas since 1898.

[Aron Simkins, MD @dr_simkins]

@nickshirleyy Thanks Nick

[Shaun Maguire @shaunmmaguire]

The Somali daycare fraud never happened

Zohran isn’t a communist

Maduro was the good guy

~~~

These are mainstream Democrat positions right now — you can see that they’re false just by opening your eyes

[US Holocaust Museum @HolocaustMuseum]

There’s a good reason the US and dozens of other countries and cities have adopted the IHRA definition of antisemitism. When leaders move to revoke it, like what happened today in New York, it should alarm everyone—especially as violence against Jews is dangerously escalating.

[Aron Simkins, MD @dr_simkins]

@dlLambo Kidnapping children is not "armed resistance" is terrorism.

[Adam Zivo @AdamZivo]

One was a Holocaust.
The other was not.

[Tali Goldsheft @TaliGoldsheft]

Never forget that hostages are being released and the war is ending—and the only reason this didn’t happen sooner is because much of the world, including “humanitarian” organizations and the UN, sided with Hamas.

Never, ever forget.

[Jack Altman @jaltma]

High agency is believing you can learn new things and work hard to solve tough problems no matter how complicated.

Low agency is sitting around making fun of people who try.

[Yehuda Teitelbaum @chalavyishmael]

The Yevsektsiya were Jews. They blamed “Zionists” and traditional Jews for alienating Soviet society. They believed that if Jews behaved properly and complied with Communism, the regime would treat them well. When they were no longer useful, the Yevsektsiya were disbanded. Their members were executed or sent to labor camps.

The Antizionist League of Iraq were Jews too. They thought Zionists were the problem. They believed that if Jews in Iraq distanced themselves from the idea of a Jewish state, all the hatred would fade away. They were wrong. The League was dissolved, its leaders imprisoned, and Iraq’s Jews were slaughtered in the Farhud and driven out. Nobody asked whether they were Zionists before burning their homes or stabbing them in the streets.

A hundred years ago, Baghdad was more Jewish than New York City is today. Now there are fewer than ten Jews in the entire country. Trying to prove that you’re one of the “good Jews” never works.

The same story played out in Germany. Jews there were the most assimilated in the world — cultured, loyal, and proud Germans. They thought the “bad Jews” were the Eastern European immigrants. The Association of German National Jews, who sought to align themselves with the Nazi Party, was outlawed. They were deported and burned along with the rest of European Jewry. Today, there are fewer Jews in all of Europe than there are Israeli Arabs in Israel. So much for Europe lecturing Israel about tolerance.

Once a society starts stigmatizing Jews — or even just a subset of Jews — the writing is on the wall. Assimilation and appeasement do not work. Explaining ourselves kindly and hoping to be accepted as the “good ones” does not work.

We are living in a dangerous time for Jews. The United States and perhaps Argentina are the last places where Jews are not broadly stigmatized. But that is changing. In a 2023 Harvard-Harris poll, two-thirds of Americans aged 18 to 24 said “Jews as a class are oppressors and should be treated that way.” That is the future of public opinion.

We have no choice but to name antizionism for what it is. And we must do it now.

Because if “anti-Zionism” were really about Bibi, it wouldn’t have existed before Israel was founded. And yet Jews were being slaughtered under that same banner for centuries.

The truth is simple. Antizionism is a hate movement with hundreds of years of Jewish blood on its hands. It is systemic. It is global. It is deadly.

Kind explanations and compliance have never saved us. Only clarity, courage, and truth have.